Thematics Asset Management has raised its investment in Vertex Pharmaceuticals Incorporated by 19.2% during the third quarter of 2024, as detailed in the firm’s latest Form 13F filing with the Securities and Exchange Commission (SEC). The asset management firm now holds a total of 12,629 shares in Vertex, having acquired an additional 2,031 shares during this period. The value of Thematics’ holdings in Vertex Pharmaceuticals stands at approximately $4.95 million as of the recent filing.
Several other institutional investors have also adjusted their positions in Vertex Pharmaceuticals. Chesapeake Asset Management LLC increased its stake by 110.0%, now owning 63 shares valued at approximately $25,000 after acquiring 33 shares last quarter. Similarly, Colonial Trust Co SC raised its position in Vertex by 118.8%, bringing its total to 70 shares worth around $27,000 following a purchase of 38 shares.
In addition, Total Investment Management Inc. established a new stake valued at about $33,000 during the second quarter. Financial Network Wealth Advisors LLC also boosted its stake by 50.9%, owning 86 shares currently estimated at $34,000 after an additional purchase of 29 shares. Y.D. More Investments Ltd saw a significant increase of 345.0%, now holding 89 shares valued at approximately $35,000.
Overall, institutional investors and hedge funds collectively own 90.96% of Vertex Pharmaceuticals’ stock, reflecting strong confidence in the company.
Insider Trading Activity
In related developments, insider trading activity has also been notable. On February 25, 2024, Executive Vice President Mark E. Bunnage sold 620 shares at an average price of $486.35, totaling $301,537. Following this transaction, Bunnage’s direct ownership in Vertex decreased by 7.84%, leaving him with 7,284 shares valued at approximately $3.54 million.
Another insider, EVP Ourania Tatsis, sold 260 shares on the same date for a total of $126,451. After this transaction, Tatsis owns 46,763 shares valued at around $22.74 million, representing a 0.55% decrease in ownership. Over the last three months, insiders have sold 91,156 shares for a combined total of $42.85 million, while company insiders hold 0.20% of the stock.
Vertex Pharmaceuticals Financial Performance
Vertex Pharmaceuticals reported its quarterly earnings results on February 12, 2024. The company announced earnings per share of $5.03, slightly below the consensus estimate of $5.05. Despite this, Vertex achieved a net margin of 32.94% and a return on equity of 24.30%. The revenue for the quarter reached $3.19 billion, which surpassed analyst expectations of $3.18 billion. This marks a 9.5% increase in revenue compared to the same quarter last year when the company posted earnings of $3.98 per share.
Looking ahead, analysts predict that Vertex Pharmaceuticals will report earnings per share of $15.63 for the current fiscal year.
Analyst Ratings and Price Targets
Recent evaluations from various analysts indicate a consensus rating of “Moderate Buy” for Vertex Pharmaceuticals. Weiss Ratings upgraded the stock from a “hold (c+)” to a “buy (b-)” rating in early February. Jefferies Financial Group initiated coverage, issuing a “buy” rating with a price target of $580.00. Morgan Stanley raised its price objective from $570.00 to $596.00 and assigned an “overweight” rating.
Furthermore, Evercore increased its target price from $475.00 to $530.00, giving the stock an “outperform” rating. Citigroup also raised its target from $575.00 to $585.00, maintaining a “buy” rating. Currently, 23 analysts have assigned a “Buy” rating while five have issued a “Hold” rating, with a consensus target price of $553.36 based on data from MarketBeat.com.
Vertex Pharmaceuticals, headquartered in Boston, focuses on developing therapies for serious diseases. Established in 1989, the company is particularly recognized for its groundbreaking work in cystic fibrosis, having developed therapies that target the underlying causes of the disease rather than merely addressing its symptoms. Vertex operates globally, serving patients and healthcare systems across various international markets, solidifying its reputation as a leader in biotechnology.
